1. Division of Allergy, Pulmonary, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, Tennessee;
2. National Reference Centre for Rare Pulmonary Diseases (Orphalung), Louis Pradel Hospital, ERN-LUNG, Lyon, France;
3. Claude Bernard University Lyon 1, UMR754, INRAE, Lyon, France;
4. PulmonIx, LLC, at Cone Health, Greensboro, North Carolina;
5. Department of Pneumology, Unit for Interstitial Lung Diseases, University Hospitals Leuven, Leuven, Belgium;
6. National Heart and Lung Institute, Imperial College London, London, United Kingdom;
7. Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah Health, Salt Lake City, Utah;
8. Pneumology Department, Mainz Lung Center, Mainz University Medical Center and Marienhaus Clinic Mainz, Mainz, Germany;
9. ILD Unit, Pulmonology Department, Hospital Universitario de la Princesa, Autonoma de Madrid, Madrid, Spain;
10. Department of Medicine and Centre for Heart Lung Innovation, University of British Columbia, Vancouver, British Columbia, Canada;
11. Department of Radiology, University of California, Los Angeles, California;
12. MedQIA LLC, Los Angeles, California;
13. Pliant Therapeutics, Inc., South San Francisco, California; and
14. Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan